Equities

Sunho Biologics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Sunho Biologics Inc

Actions
  • Price (HKD)6.39
  • Today's Change0.000 / 0.00%
  • Shares traded18.60k
  • 1 Year change+61.36%
  • Beta--
Data delayed at least 15 minutes, as of Feb 12 2026 06:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sunho Biologics Inc is a clinical stage biopharmaceutical company mainly focusing on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. The Company is also engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-92.97m
  • Incorporated2021
  • Employees128.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.